原发性中枢神经系统淋巴瘤患者静脉血栓栓塞的发生率、危险因素与管理
该回顾性研究纳入2002年至2020年弗吉尼亚大学78例原发性中枢神经系统淋巴瘤(PCNSL)患者,发现31%(24/78)发生静脉血栓栓塞(VTE),中位时间3个月。既往VTE、活动受限、基线血红蛋白<10 g/dL及糖尿病史与VTE风险升高相关。抗凝可预防多数复发且无颅内出血,但最佳管理尚不确定。
要点
- PCNSL患者VTE发生率高(31%),多集中于诊断后前几个月。
- 既往VTE、活动受限、血红蛋白<10 g/dL、糖尿病史与VTE风险升高相关。
- 抗凝治疗可预防多数复发VTE且未观察到颅内出血,但最佳方案未定。
核心结论
- PCNSL患者VTE风险高,多数发生在诊断后最初几个月。
- 既往VTE、糖尿病(1型或2型)、活动受限或血红蛋白<10 g/dL可能易感此并发症。
- 抗凝在多数患者中预防了复发VTE且无颅内出血,但最佳管理尚不确定。
研究设计与样本
- 回顾性研究,纳入2002年2月1日至2020年4月1日弗吉尼亚大学78例PCNSL患者。
主要发现
- 31%(24/78)患者发生VTE,其中12.8%(10/78)单纯深静脉血栓,11.5%(9/78)孤立性肺栓塞,6.4%(5/78)两者兼有。
- PCNSL诊断至VTE的中位时间为3个月。
- 单因素竞争风险分析显示既往VTE(p < 0.001)、活动受限(p = 0.035)、基线血红蛋白<10 g/dL(p = 0.025)及糖尿病史(1型或2型)(p = 0.007)与VTE风险升高相关。
- 急性期34.8%(8/23)使用肝素,65.2%(15/23)使用低分子肝素;长期25.0%(6/24)使用华法林,41.7%(10/24)使用低分子肝素,33.3%(8/24)使用直接口服抗凝药。
- 6/24例患者出现复发性VTE,其中4例发生在抗凝期间;5例置入下腔静脉滤器并同时口服抗凝,1例在停抗凝后发生下腔静脉血栓。
临床怎么用
- 对PCNSL患者应警惕VTE风险,尤其诊断后前几个月。
- 评估既往VTE、糖尿病史、活动状态及基线血红蛋白以识别高危患者。
- 抗凝治疗可考虑用于预防复发VTE,但需个体化评估。
局限性
- 回顾性研究,样本量较小(78例)。
- 单中心研究,结果外推需谨慎。
- 最佳抗凝管理尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Venous thromboembolism (VTE) is a known complication of malignancy. While brain tumors in general predispose to VTE, the incidence in primary central nervous system lymphoma (PCNSL) is poorly characterized. We sought to characterize incidence, risk factors, management, and outcome of VTE in PCNSL METHOD: Retrospective study of 78 PCNSL patients from 2/1/2002 to 4/1/2020 at the University of Virginia RESULTS: 31% (24/78) of patients developed VTE. 12.8% (10/78) had deep venous thrombosis (DVT) alone, 11.5% (9/78) isolated pulmonary embolism (PE) and 6.4% (5/78) both. The median time from PCNSL diagnosis to VTE was 3 months. In a univariate competing risks analysis, previous VTE (p < 0.001), impaired ambulation (p = 0.035), baseline hemoglobin < 10 g/dL (p = 0.025) and history of diabetes mellitus (type 1 or 2) (p = 0.007) were associated with increased VTE risk. 34.8% were anticoagulated acutely with heparin (8/23) or 65.2% LMWH (15/23), and 25.0% (6/24) received warfarin, 41.7% (10/24) LMWH, and 33.3% (8/24) DOACs long-term. One adverse event was attributable to anticoagulation (arm hematoma with hemoglobin decrease). Five patients received IVC filters with concomitant oral anticoagulation; one experienced IVC thrombosis after anticoagulation discontinuation. Six of the 24 patients experienced recurrent VTE, four while anticoagulated. CONCLUSION: Patients with PCNSL are at high risk of VTE, most of which accrues in the first few months. History of VTE, diabetes mellitus (type 1 or 2), impaired ambulatory status, or hemoglobin < 10 g/dL may predispose patients to this complication. While optimal management is uncertain, anticoagulation prevented recurrent VTE in most patients without intracranial bleeding.
引用
- Saito M, Wages NA, Schiff D, et al. Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma. J Neurooncol. 2021. PMID: 34164780. doi:10.1007/s11060-021-03791-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。